相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid A Prospective Multicountry Study
Molly F. Franke et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis
Dalin Rifat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
Deepak Almeida et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
Kelly E. Dooley et al.
LANCET INFECTIOUS DISEASES (2021)
One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics
Hee-Jeong Yang et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
S. Koirala et al.
PULMONOLOGY (2021)
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
S. Oelofse et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2021)
Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study
James C. M. Brust et al.
CLINICAL INFECTIOUS DISEASES (2021)
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Camus Nimmo et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Reduced susceptibility and resistance to be daquiline in clinical M. tuberculosis isolates
Irina Peretokina et al.
JOURNAL OF INFECTION (2020)
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor
Norimitsu Hariguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3
Giulia Degiacomi et al.
APPLIED SCIENCES-BASEL (2020)
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Zhiyi Lan et al.
LANCET RESPIRATORY MEDICINE (2020)
Telacebec (Q203), a New Antituberculosis Agent
Veronique R. de Jager et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The looming threat of bedaquiline resistance in tuberculosis
Chen-Yuan Chiang et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini
D. Vambe et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2020)
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis
Vikram Saini et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
Zarir F. Udwadia et al.
BMC INFECTIOUS DISEASES (2019)
Advances in clinical trial design for development of new TB treatments: A call for innovation
Christian Lienhardt et al.
PLOS MEDICINE (2019)
Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo
Ye Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment
David Tenero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
Geraint Davies et al.
PLOS MEDICINE (2019)
Tuberculosis drug discovery in the CRISPR era
Jeremy Rock
PLOS PATHOGENS (2019)
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
A. D. Pranger et al.
DRUGS (2019)
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Conor D. Tweed et al.
LANCET RESPIRATORY MEDICINE (2019)
Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects
Yewon Choi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa
Olatunde Olayanju et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study
Gabriella Ferlazzo et al.
LANCET INFECTIOUS DISEASES (2018)
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis
Mamoru Fujiwara et al.
TUBERCULOSIS (2018)
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
Rafael Baptista et al.
SCIENTIFIC REPORTS (2018)
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study
Kathryn Schnippel et al.
LANCET RESPIRATORY MEDICINE (2018)
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Norbert Ndjeka et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention
Thi Van Anh Nguyen et al.
CLINICAL INFECTIOUS DISEASES (2018)
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Lorenzo Guglielmetti et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence
Emanuele Pontali et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree et al.
LANCET INFECTIOUS DISEASES (2017)
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
Nicolas Blondiaux et al.
SCIENCE (2017)
Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis
Murat Cokol et al.
SCIENCE ADVANCES (2017)
Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis
Xiuhao Chen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials
Laura J. Bonnett et al.
CLINICAL INFECTIOUS DISEASES (2017)
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis
Rokeya Tasneen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis
Alexander S. Pym et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials
Riya Moodley et al.
EUROPEAN RESPIRATORY REVIEW (2016)
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
Norbert Heinrich et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use
Simon Tiberi et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
Robert S. Wallis et al.
PLOS ONE (2014)
Clofazimine: current status and future prospects
Moloko C. Cholo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon et al.
LANCET (2012)
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis
Robert S. Wallis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Drug repositioning in the treatment of malaria and TB
Alexis Nzila et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Armand Van Deun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model
K. N. Williams et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Vadim Makarov et al.
SCIENCE (2009)
High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
Thierry Christophe et al.
PLOS PATHOGENS (2009)
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis
Eric Nuermberger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis
R. Rustomjee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Ramandeep Singh et al.
SCIENCE (2008)
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis
M. Ibrahim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice
Makoto Matsumoto et al.
PLOS MEDICINE (2006)
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration
Nacer Lounis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
分享论文
